Standard Biotools Inc - Asset Resilience Ratio

Latest as of June 2026: 32.95%

Standard Biotools Inc (LAB) has an Asset Resilience Ratio of 32.95% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See LAB working capital efficiency to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

$206.69 Million
Cash + Short-term Investments

Total Assets

$627.22 Million
All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2006–2025)

This chart shows how Standard Biotools Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Standard Biotools Inc.

Liquid Assets Composition Over Time

This chart breaks down Standard Biotools Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore investment intensity of Standard Biotools Inc to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $206.69 Million 32.95%
Total Liquid Assets $206.69 Million 32.95%

Asset Resilience Insights

  • Very High Liquidity: Standard Biotools Inc maintains exceptional liquid asset reserves at 32.95% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Standard Biotools Inc Industry Peers by Asset Resilience Ratio

Compare Standard Biotools Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Medtronic plc
SA:MDTC34
Medical Devices 7.82%
Demant A/S
CO:DEMANT
Medical Devices -2.59%
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
Medical Devices 0.84%
Jafron Biomedical Co Ltd
SHE:300529
Medical Devices 34.37%
Sinocare Inc
SHE:300298
Medical Devices 3.53%
Emvision Medical Devices Ltd
AU:EMV
Medical Devices 0.06%
Theradiag SA
PA:ALTHE
Medical Devices 15.59%
Biosynex
PA:ALBIO
Medical Devices 3.35%

Annual Asset Resilience Ratio for Standard Biotools Inc (2006–2025)

The table below shows the annual Asset Resilience Ratio data for Standard Biotools Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 12.22% $69.36 Million $567.75 Million -8.38pp
2024-12-31 20.60% $126.15 Million $612.34 Million +1.04pp
2023-12-31 19.56% $63.19 Million $323.07 Million -22.92pp
2022-12-31 42.47% $165.78 Million $390.31 Million +32.14pp
2021-12-31 10.34% $28.45 Million $275.21 Million +3.96pp
2020-12-31 6.37% $20.70 Million $324.76 Million -9.50pp
2019-12-31 15.87% $42.02 Million $264.81 Million -9.72pp
2018-12-31 25.59% $77.72 Million $303.65 Million +10.63pp
2017-12-31 14.97% $43.01 Million $287.35 Million +0.13pp
2016-12-31 14.83% $45.45 Million $306.39 Million -2.92pp
2015-12-31 17.75% $65.86 Million $371.06 Million -2.27pp
2014-12-31 20.02% $81.59 Million $407.56 Million -21.96pp
2013-12-31 41.98% $49.08 Million $116.92 Million +23.20pp
2012-12-31 18.78% $21.36 Million $113.73 Million -31.53pp
2011-12-31 50.32% $39.91 Million $79.33 Million +38.84pp
2007-12-31 11.48% $6.29 Million $54.78 Million +10.11pp
2006-12-31 1.37% $500.00K $36.49 Million --
pp = percentage points

About Standard Biotools Inc

NASDAQ:LAB USA Medical Devices
Market Cap
$286.58 Million
Market Cap Rank
#15384 Global
#3630 in USA
Share Price
$0.73
Change (1 day)
+2.82%
52-Week Range
$0.64 - $1.68
All Time High
$14.36
About

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consum… Read more